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Key Clinical Message
Early diagnosis of potentially life-threatening autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy (APECED) is crucial, but is often delayed due
to the clinical heterogeneity of the disorder. Even in the absence of the classic
disease triad of chronic mucocutaneous candidiasis, hypoparathyroidism, and
adrenocortical insufficiency, a diagnosis of APECED should be considered in
children who have hypoparathyroidism and chronic keratitis, with a past medi-
cal history showing a mild and transient Candida infection.
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Introduction
In children, the main causes of hypoparathyroidism
include DiGeorge syndrome (22q11.2 deletion syndrome),
parathyroid agenesis, mutations of the calcium-sensing
receptor (CASR) or parathyroid hormone (PTH) genes,
and pseudohypoparathyroidism. The disease is character-
ized by low parathyroid hormone (PTH) levels, hypocal-
caemia, and hyperphosphatemia, and can be revealed by
tetany, irritability, and seizure. Patients with autoimmune
polyendocrinopathy-candidiasis-ectodermal dystrophy
(APECED) also suffer from hypoparathyroidism along
with chronic mucocutaneous candidiasis and Addison’s
disease (adrenocortical insufficiency), although the pres-
ence of two of this classic triad is diagnostic [1]. A
spectrum of other autoimmune endocrine and ectodermal
disorders such as type 1 diabetes mellitus, thyroid
autoimmunity, hypogonadism, pernicious anemia, kerati-
tis, and vitiligo may also manifest [1]. The disease is
caused by loss-of-function mutations in the autoimmune
regulator (AIRE) gene, which prevent the AIRE transcrip-
tion factor from acting to ensure negative selection of
autoreactive T cells in the thymus [2]. Due to the failure
of immunological tolerance, affected organs are infiltrated
by autoreactive T lymphocytes, and antibodies against tis-
sue-specific proteins such as NACHT leucine-rich-repeat
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protein 5 (NALP5), calcium-sensing receptor (CaSR), and
tyrosine hydroxylase can be present in patients’ sera [3,
4]. These often associate with certain disease components
[1, 3, 4].
The first disease components, most usually chronic
mucocutaneous candidiasis and hypoparathyroidism, nor-
mally emerge in childhood, but the heterogeneity of
APECED in terms of its initial clinical presentation can
make it challenging to identify and, typically, the condi-
tion is diagnosed after the first decade of life [1, 5]. More
recently, the presence of antibodies against interferon
(IFN)-x and IFN-a2 has been shown to aid diagnosis due
to their sensitivity and relative specificity for APECED [6,
7]. Anti-interleukin (IL)-22, anti-IL-17A, and anti-IL-17F
antibodies are also common [8]. In addition, mutational
analysis of AIRE enables more than 95% of cases to be
identified [2]. Here, we report on an unusual clinical pre-
sentation of APECED in a young girl who had an early-
onset of hypoparathyroidism and chronic keratitis, and
who had experienced previously a mild and transient
mucocutaneous candidiasis.
Case History and Examination
A 3-year-old girl was admitted to our pediatric emergency
unit after having repeated carpopedal spasms, dyskinesia,
and disequilibrium. The girl’s medical history showed that
she had presented with her first episode of spasm with
fever some months before experiencing a mild and tran-
sient mucocutaneous candidiasis at 1 year of age, and
needed an ophthalmological examination at 2 years
because of photophobia and lacrimation at which time
she was diagnosed with bilateral keratoconjunctivitis of
unknown etiology. She was born from healthy consan-
guineous parents without any neonatal problems, and had
one healthy sibling. The patient’s physical examination
was unremarkable, but ocular assessment revealed chronic
keratitis with progressive corneal scars (Fig. 1).
Laboratory Evaluations
The patient’s spasms were indicative of hypocalcaemia
and, indeed, biochemical analyses revealed a severely low
serum calcium level of 1.28 mmol/L (normal range, 2.2–
2.7 mmol/L). This was coupled with a high serum phos-
phate level of 2.56 mmol/L (normal range, 1.3–
1.85 mmol/L) indicating profound hyperphosphatemia.
These evaluations, together with a low blood PTH con-
centration of <3 pg/mL (normal range, 10–80 pg/mL)
and a decreased urine calcium: creatinine ratio of
0.06 mmol/L (normal range, 0.2–0.7 mmol/L), suggested
that the patient had hypoparathyroidism. The serum level
of 25-hydroxyvitamin D at 24 nmol/L (normal range, 80–
250 nmol/L) was low. Creatinine at 34 lmol/L (normal
range, 23–37 lmol/L) and magnesium at 0.83 mmol/L
(normal range, 0.75–1.0 mmol/L) were at normal serum
concentrations. Serum levels of thyroid-stimulating hor-
mone (TSH) at 2.2 mIU/L (normal range, 0.4–3.1 mIU/
L), and Free T4 (the active form of thyroxine) at
18.6 pmol/L (normal range, 11.1–20.6 pmol/L) were
within the normal ranges, indicating unaffected thyroid
function.
Differential Diagnosis and
Investigations
The absence of dysmorphy, cardiac malformation, and
immunodeficiency ruled out the diagnosis of DiGeorge
syndrome as a cause of the patient’s hypoparathyroidism.
Lack of mutations of the CASR gene also precluded this
as the basis for the patient’s severe hypocalcaemia. Ultra-
sonography examination also showed normal parathyroid
glands. Despite the absence of the classic disease triad and
lack of autoimmunity in her parents or sibling, we con-
sidered APECED as the possible diagnosis based on the
association of hypoparathyroidism with a minor APECED
component chronic keratitis, and a previous mild and
transient mucocutaneous candidiasis.
After obtaining written consent, blood samples were
collected from the child and her parents for genetic analy-
sis of the AIRE gene using peripheral blood mononuclear
cells (PBMCs) as a source of DNA. Subsequently, the
diagnosis was confirmed by an AIRE gene frameshift
mutation c.931delT (p.C311fsX376) affecting codon 311
of exon 8. This mutation leads to the production of a
downstream stop codon at codon 376 and thus, a short-
ened and a nonfunctional AIRE protein lacking both
plant homeodomain (PHD) 1 and 2 zinc fingers (Fig. 2).
The patient was homozygous for this recessive mutation.
Both parents were c.931delT heterozygotes.
Credence was added to the diagnosis by the detection
of antibodies against IFN-a2A (antibody index, 5.2; nor-Figure 1. Ocular scars of recurrent chronic keratitis.
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mal range, 0.62–1.72), IFN-x (antibody index, 2.79;
normal range, 0.97–1.08), interleukin (IL)-22 (antibody
index, 44.2; normal range, 0.87–1.39), IL-17F (antibody
index, 16.2; normal range, 0.86–1.19). However, the
patient was sero-negative for anti-IL-17A (antibody index,
0.97; normal range, 0.78–1.61), anti-IFN-k (antibody
index, 0.89; normal range, 0.85–1.20), and anti-IFN-b1a
antibodies.
Further serological investigations indicated the patient
was positive for antibodies against the CaSR (antibody
index, 33.2; normal range, 0.97–1.22), but in CaSR func-
tional assays, these did not activate the receptor. Anti-
NALP5 antibodies were not detected (antibody index,
1.12; normal range, 0.79–1.19). The patient had no
humoral autoimmune response against the adrenal glands:
anti-21-hydroxylase antibodies that are markers for the
prevalent APECED component Addison’s disease were
absent. Similarly, the patient was sero-negative for the
major markers of type 1 diabetes mellitus, namely anti-
islet cell, anti-glutamic acid decarboxylase (GAD65), and
anti-tyrosine phosphatase-like protein IA2 antibodies.
Thyroid autoimmunity was not apparent as indicated by
normal function tests and an absence of anti-thyroid per-
oxidase and anti-thyroglobulin antibodies. Antibodies
directed against actin, mitochondria, liver kidney micro-
somes, the nucleus, and dsDNA were not present.
Treatment and Follow-up
Treatment of hypoparathyroidism consisted of combining
calcium (0.5 g three times daily), 1,25-dihydroxyvitamin
D3 (0.5 lg once daily) associated with 25-hydroxyvitamin
D3 (100,000 IU every 3 months), and phosphate binders
sevelamer hydrochloride, in order to alleviate spasms and
return serum calcium and phosphate levels to 2.20 mmol/
L and 1.66 mmol/L, respectively. However, the ocular
lesions progressed and led to the loss of visual acuity and
irreversible corneal scarring in spite of a topical treatment
with steroids. A cornea graft is under consideration.
Discussion
At the time of diagnosis, the 3-year-old patient did not
have the classic APECED disease triad of chronic muco-
cutaneous candidiasis, hypoparathyroidism, and adreno-
cortical insufficiency, and familial evidence of the
disorder was lacking. In addition, aside from
hypoparathyroidism and chronic keratitis, none of the
many other APECED-associated diseases were evident
either clinically or immunologically. The diagnosis was
therefore confirmed by detecting anti-IFN-x and anti-
IFN-a2 antibodies, and sequencing of the AIRE gene for
potential mutations.
As part of the syndrome, chronic mucocutaneous can-
didiasis is apparent in 70% of cases by age 10 rising to
97% by age 30 and is the earliest and most common sign
of APECED [1]. Prior to the diagnosis, our patient had
suffered from only a single episode of mild and transient
mucocutaneous candidiasis. The patient presented with
hypoparathyroidism, the most frequent endocrine feature
of APECED with a prevalence of 66% by age 10 and
85% by age 30 [1]. Like other endocrinopathies in
APECED, the cause of hypoparathyroidism is considered
to be autoimmune. Sporadic case reports of idiopathic
Figure 2. Schematic representation of the AIRE protein. Shown are selected mutations, including the C311fsX376 (c.931delT) variant; the
caspase recruitment domain (CARD); the SP100, AIRE1, NucP41/P75, DEAF1 domain (SAND); two plant homeodomain (PHD) zinc finger motifs;
and the proline-rich region (PRR). Amino acid residues of the AIRE protein are numbered from the amino (N) terminus to the carboxy (C)
terminus.
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hypoparathyroidism have documented lymphocytic and
plasma cell infiltration of the parathyroid [9], as well as
complement-mediated damage of the glands [10]. How-
ever, our patient had a normal parathyroid examination
negating immunologically damaged glands as a cause of
her hypoparathyroidism. Anti-CaSR antibodies which can
have an etiological role in hypoparathyroidism by activat-
ing the CaSR and thus inhibiting PTH secretion, have
been identified in a small number of cases of isolated
hypoparathyroidism and APECED [11–13]. In our
patient, although a humoral autoimmune response
against the CaSR was detected, the antibodies did not
appear to stimulate the receptor. Conceivably, anti-CaSR-
activating antibodies may have been at too low level to be
demonstrated with our assay. Interestingly, the patient
was negative for anti-NALP5 antibodies which are
reported markers for hypoparathyroidism in APECED
[4]. However, these may develop in the patient over time.
Addison’s disease appears most commonly following
mucocutaneous candidiasis and hypoparathyroidism, and
by age 10 in 40% of patients and by age 30 in 78% of
patients [1]. There was no clinical or immunological evi-
dence of adrenocortical insufficiency in the current case,
but diagnosis of adrenal failure is crucial to avoid the risk
of a fatal adrenal crisis. The potential development of
Addison’s disease will therefore be monitored as a diag-
nosis of APECED, meaning it is highly likely that this will
occur later in the patient’s lifetime given her young age.
The only nonendocrine disease identified in the patient
at diagnosis was keratitis, the onset of which was rapid,
probably before hypoparathyroidism. Keratitis is the first
manifestation in only 3–14% of APECED cases, but is usu-
ally an early component and affects 25–50% of patients
[1]. Symptoms include photophobia, blepharospasm, con-
junctival redness, and decreased visual acuity, all of which
were noted in our patient [14]. Although the pathophysi-
ology of keratopathy is not fully understood, immune cells
seem to play an essential role: in AIRE-deficient mice, cor-
neal and conjunctival epitheliums, stroma and meibomian
glands are infiltrated by CD4+ and CD8+ T cells [15]. Mei-
bomian gland destruction and the loss of goblet cells result
in the loss of tear film and may trigger inflammation [16],
although the subsequent progression of epithelial edema
and superficial opacity can be reversed under topical ster-
oid therapy. Recurrences are frequent and lead to irre-
versible scarring (nodule and pannus formation), deep
vascularisation, and blindness [14, 16].
Crucial to the diagnosis of APECED in this unusual
case was the detection of typical anti-IFN-x and anti-
IFN-a2 antibodies [6, 7]. Furthermore, antibodies against
IL-22 and IL-17F were present [8]. The Th17 cell-associ-
ated cytokines, IL-17A, IL-17F, and IL-22, play a key role
in protecting against Candida infection [17]. High levels
of antibodies to the IL-17 family of cytokines are typically
produced by patients with APECED and are suggested to
predispose to candidiasis by virtue of their neutralizing
activities [18]. Indeed, APECED patients with no or mild
candidiasis have low or undetectable levels of antibodies
against IL-17A, IL-17F, and IL-22 [18, 19]. Compatible
with this theory, our patient was sero-negative for anti-
IL-17A antibodies. However, she did have high levels of
anti-IL-22 and anti-IL-17F antibodies, an observation
analogous to a report of five APECED patients in which a
lack of Candida infection correlated only with an absence
of antibodies against IL-17A [19].
The final confirmation of APECED came with the iden-
tification of homozygous AIRE gene mutation c.del931T, a
rare variant with only two previously documented cases
[2, 20]. The first was described in a French patient ana-
lyzed as part of a series of 112 APECED patients from var-
ious ethnic backgrounds [2]. Although the exact clinical
details of the patient were not given, the individual had at
least two of the classic APECED triad of hypoparathy-
roidism, chronic mucocutaneous candidiasis, and adreno-
cortical insufficiency. A second case with this AIRE gene
mutation was reported in a young male Sicilian [20].
Onset was at 6 years of age and, similar to our patient, he
experienced candidiasis and hypoparathyroidism. In con-
trast, he suffered also from malabsorption, alopecia,
enamel hypoplasia, and nephrocalcinosis, but not from
keratitis. Overall, the c.del931T mutation does not appear
to correlate with a specific clinical APECED phenotype.
Early diagnosis of APECED, a potentially life-threaten-
ing condition, is crucial. However, because of the clinical
heterogeneity of the disorder, there is often a delay
between the first symptoms and identification of the dis-
ease with a mean gap of 10.2 years [5]. As seen from
this study, even in the absence of the main triad of dis-
orders of chronic mucocutaneous candidiasis,
hypoparathyroidism, and adrenocortical insufficiency,
APECED should be considered in young patients who
have hypoparathyroidism and chronic keratitis, and a
past medical history showing a mild and transient Can-
dida infection. An initial diagnosis can be confirmed
quickly by serological testing for anti-IFN-x and anti-
IFN-a2 antibodies, and sequencing of the AIRE gene
where available. Long-term follow-up will be mandatory
to screen for additional organ-specific autoimmunity
which could develop over the following years and dec-
ades.
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